Inventiva has appointed Axel-Sven Malkomes as Chief Financial Officer (CFO). Malkomes has over 30 years of experience in investment banking, corporate leadership and private equity across life sciences and healthcare.
He was most recently CFO at CureVac, an mRNA company focused on oncology and infectious diseases. Prior to CureVac, he was CFO at Cardior, a non-coding, RNA-based cardiology biotech company, where he prepared the company for capital markets and co-led subsequent acquisition by Novo Nordisk.
Earlier, he held the role of CFO and Chief Business Officer at Medigene, an immuno-oncology company focused on cell therapy.
Malkomes also spent time reshaping the overall business portfolio at Merck KGaA through mergers and acquisitions and business development partnerships as well as later becoming CEO of a Merck KGaA Group company.
His investment banking and private equity experience comes from Lehman Brothers and Barclays, as well as several years at 3i Group as senior executive of Global Healthcare Buyouts.
“I am delighted to welcome Axel-Sven to the leadership team,”said Andrew Obenshain, CEO of Inventiva.
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need.